Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:2009:420759.
doi: 10.1155/2009/420759. Epub 2009 Dec 8.

Biologic agents-a panacea for inflammatory arthritis or not?

J Ninan  1 , Malcolm D Smith, M Dugar, Karen O'Brien, Michael Ahern
Affiliations

Biologic agents-a panacea for inflammatory arthritis or not?

J Ninan et al. Int J Rheumatol. 2009.

Abstract

Aim. To describe the retention rates for biological therapies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) in a clinical setting. Methods. All patients managed in a dedicated biological therapy clinic in a teaching hospital in Australia were assessed for continuation on biological treatments and reasons for switching to an alternative biological agent or cessation of treatment. Results. There was a lower retention rate for RA patients on biological therapies compared to PsA and AS patients and the retention rate for RA patients was lower than that reported in RCTs. Conclusions. The retention rate on biological therapies for RA patients was lower in the clinic setting than what is reported in RCTs. The reasons for the lower retention rate in the clinical setting are discussed but no clear determinants for nonresponse to biological agents were identifiable. These agents have very limited steroid sparing effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier survival curves for first biologic agent according to diagnosis P-value .0082.
See this image and copyright information in PMC

References

    1. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of Etanercept and Methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. The Lancet. 2004;363(9410):675–681. - PubMed
    1. Lipsky PE, van der Heijde DMFM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy group. The New England Journal of Medicine. 2000;343(22):1594–1602. - PubMed
    1. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and Rheumatism. 2003;48(1):35–45. - PubMed
    1. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis & Rheumatism. 2006;54(9):2793–2806. - PubMed
    1. Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis & Rheumatism. 2008;58(4):953–963. - PubMed